THE US Food and Drug
Administration has approved
Gilotrif (afatinib) for patients with
metastatic non-small cell lung
cancer whose tumours express
specific types of epidermal growth
factor receptor (EGFR) gene
mutations, as detected by an FDAapproved
test.
Gilotrif is a tyrosine kinase
inhibitor which works by blocking
proteins that promote the
development of cancerous cells.
The treatment is being approved
concurrently with the therascreen
EGFR RGQ PCR Kit, a companion
diagnostic kit that helps determine
if a patient’s lung cancer cells
express the EGFR mutations.
Gilogrif is marketed by Boehringer
Ingelheim, while the accompanying
test is manufactured by UK-based
QUIAGEN Manchester Limited.
In a clinical trial patients receiving
Gilotrif had delayed tumour growth
compared to chemotherapy.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.